NEW YORK, May 27 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.reportlinker.com/p0202879/Neutropenia---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData's pharmaceutical and healthcare report offering, "Neutropenia – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global lung cancer market. This pharma report identifies the key trends shaping and driving the global neutropenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neutropenia sector.
GlobalData estimated the global neutropenia market to grow by 4% annually for the next seven years to reach $8.6 billion in 2016. This moderate growth is primarily attributed to the increase in the uptake of biologics and the presence of strong pipeline candidates. The growth will be supported by increases in incidence and prevalence of the disease, and the high prescription rate of the currently marketed products. GlobalData determined that the global neutropenia market is moderately served by the current product options and significant Scope is available to new entrants that can capture value from underserved segments. Designing highly efficacious products that will encourage physician compliance is one of key challenges of this market and could provide a significant market share for any company achieving this.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The Scope of the report includes:
- Annualized global neutropenia market revenues data from 2001 to 2009, forecast for seven years to 2016.
- The geographies covered in this report are the United States (US), the Untied Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include D-alanyl-D-alanine binders, fungal cytochrome P-450 inhibitors, Granulocyte Colony Stimulating Factor (G-CSF) binders and bone marrow stimulators.
- Analysis of the current and future market competition in the global neutropenia market. The key market players covered are Amgen, Pfizer, Maxygen, Teva Pharmaceuticals and CoGenesys (which is now a part of Teva Pharmaceuticals).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future neutropenia market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global neutropenia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neutropenia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global neutropenia market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables4
1.2 List of Figures4
2 Growth Hormone Deficiency (GHD): Market Characterization 5
2.1 Overview 5
2.2 GHD Drugs Market Size 5
2.3 GHD Drugs Market Forecast and CAGR 6
2.4 Drivers and Barriers for the GHD Therapeutics Market 7
2.4.1 Drivers for the GHD therapeutics market 7
2.4.2 Barriers for the GHD therapeutics market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 GHD Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Products in the GHD Market 12
3.3.1 Genotropin 12
3.3.2 Humatrope 12
3.3.3 Nutropin 13
3.3.4 Saizen 14
3.3.5 Norditropin 15
3.4 Key Takeaway 16
4 Growth Hormone Deficiency Market: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 GHD Therapeutics – Promising Drugs under Clinical Development 19
4.4 Molecule Profile for Promising Drugs/Vaccines under Clinical Development 20
4.4.1 LB03002 (LG Life Sciences/ Biopartners) 20
4.4.2 ALTU-238 (Altus Pharmaceuticals) 20
4.4.3 ARX-201 (Ambrx/ Merck Serono) 21
4.4.4 NN8630 (Novo Nordisk A/S) 21
4.4.5 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 22
4.5 GHD Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
4.5.1 GHD Pipeline – Pipeline by Clinical Phases of Development 23
4.5.2 GHD Therapeutics – Phase III Clinical Pipeline 24
4.5.3 GHD Therapeutics – Phase II Clinical Pipeline 24
4.5.4 GHD Therapeutics – Phase I Clinical Pipeline 24
4.5.5 GHD Therapeutics – Preclinical Phase Pipeline 24
4.6 Key Takeaway 25
5 GHD Therapeutics Market: Implications for Future Market Competition 26
6 GHD Therapeutics Market: Future Players in the GHD Market 28
6.1 Introduction 28
6.2 LG Life Sciences, Korea 29
6.2.1 Overview 29
6.2.2 LB03002 (LG Life Sciences/Biopartners) 29
6.3 Altus Pharmaceuticals, the US 30
6.3.1 Overview 30
6.3.2 ALTU-238 30
6.4 Ambrx, Inc., the US 31
6.4.1 Overview 31
6.4.2 ARX-201 31
6.5 Novo Nordisk A/S, Denmark 32
6.5.1 Overview 32
6.5.2 NN8630 (Novo Nordisk A/S) 33
6.6 Ipsen S.A., France 33
6.6.1 Overview 33
6.6.2 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 34
7 GHD Therapeutics Market: Appendix 35
7.1 Market Definitions 35
7.2 Abbreviations 35
7.3 Research Methodology 36
7.3.1 Coverage 36
7.3.2 Secondary Research 37
7.3.3 Forecasting 37
7.3.4 Primary Research 40
7.3.5 Expert Panel Validation 40
7.4 Contact Us 40
7.5 Disclaimer 40
7.6 Sources 41
1.1 List of Tables
Table 1: Neutropenia Market, Revenue ($bn), 2001-2009 7
Table 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Table 3: Major Marketed Products Comparison in the Neutropenia Market, 2010 15
Table 4: Neutropenia Market– Phase III Clinical Pipeline, 2010 22
Table 5: Neutropenia Market– Phase II Clinical Pipeline, 2010 22
Table 6: Neutropenia Market– Pre Clinical Pipeline, 2010 22
Table 7: Neutropenia Market– Terminated Pipeline Molecules, 2010 23
Table 8: Neutropenia Market– Approved Pipeline Molecules, 2010 23
Table 9: Pfizer Pharmaceuticals- Blood Disorder Marketed Products, 2010 29
Table 10: Pfizer Pharmaceuticals- Blood Disorder Pipeline Products, 2010 29
Table 11: Teva Pharmaceuticals- Blood Disorder Marketed Products, 2010 31
Table 12: Teva Pharmaceuticals- Blood Disorder Pipeline Products, 2010 32
1.2 List of Figures
Figure 1: Neutropenia Market, Global, Revenue ($bn), 2001-2009 7
Figure 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Figure 3: Opportunity and Unmet Need for Neutropenia Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Neutropenia Market, 2010 12
Figure 5: Technology Trends Analytic Framework of the Neutropenia Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Neutropenia Pipeline – Description, 2010 18
Figure 7: Neutropenia Market – Clinical Pipeline by Mechanism of Action, 2010 21
Figure 8: Neutropenia Pipeline by Phase of Clinical Development, 2010 21
Figure 9: Implications for Future Market Competition in Neutropenia Market, 2010 24
Figure 10: Neutropenia Market – Clinical Pipeline by Company, 2010 25
Figure 11: GlobalData Methodology, 2010 34
Figure 12: GlobalData Market Forecasting Model, 2010 37
Companies mentioned
Maxygen
Pfizer 27
Teva Pharmaceutical Industries Limited
To order this report:
Drug and Medication Industry: Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
http://www.reportlinker.com/p0202879/Neutropenia---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Advertisement
Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData's pharmaceutical and healthcare report offering, "Neutropenia – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global lung cancer market. This pharma report identifies the key trends shaping and driving the global neutropenia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neutropenia sector.
GlobalData estimated the global neutropenia market to grow by 4% annually for the next seven years to reach $8.6 billion in 2016. This moderate growth is primarily attributed to the increase in the uptake of biologics and the presence of strong pipeline candidates. The growth will be supported by increases in incidence and prevalence of the disease, and the high prescription rate of the currently marketed products. GlobalData determined that the global neutropenia market is moderately served by the current product options and significant Scope is available to new entrants that can capture value from underserved segments. Designing highly efficacious products that will encourage physician compliance is one of key challenges of this market and could provide a significant market share for any company achieving this.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The Scope of the report includes:
- Annualized global neutropenia market revenues data from 2001 to 2009, forecast for seven years to 2016.
- The geographies covered in this report are the United States (US), the Untied Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include D-alanyl-D-alanine binders, fungal cytochrome P-450 inhibitors, Granulocyte Colony Stimulating Factor (G-CSF) binders and bone marrow stimulators.
- Analysis of the current and future market competition in the global neutropenia market. The key market players covered are Amgen, Pfizer, Maxygen, Teva Pharmaceuticals and CoGenesys (which is now a part of Teva Pharmaceuticals).
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future neutropenia market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global neutropenia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neutropenia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global neutropenia market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 3
1.1 List of Tables4
1.2 List of Figures4
2 Growth Hormone Deficiency (GHD): Market Characterization 5
2.1 Overview 5
2.2 GHD Drugs Market Size 5
2.3 GHD Drugs Market Forecast and CAGR 6
2.4 Drivers and Barriers for the GHD Therapeutics Market 7
2.4.1 Drivers for the GHD therapeutics market 7
2.4.2 Barriers for the GHD therapeutics market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 10
3 GHD Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Products in the GHD Market 12
3.3.1 Genotropin 12
3.3.2 Humatrope 12
3.3.3 Nutropin 13
3.3.4 Saizen 14
3.3.5 Norditropin 15
3.4 Key Takeaway 16
4 Growth Hormone Deficiency Market: Pipeline Assessment 17
4.1 Overview 17
4.2 Strategic Pipeline Assessment 17
4.2.1 Technology Trends Analytic Framework 17
4.3 GHD Therapeutics – Promising Drugs under Clinical Development 19
4.4 Molecule Profile for Promising Drugs/Vaccines under Clinical Development 20
4.4.1 LB03002 (LG Life Sciences/ Biopartners) 20
4.4.2 ALTU-238 (Altus Pharmaceuticals) 20
4.4.3 ARX-201 (Ambrx/ Merck Serono) 21
4.4.4 NN8630 (Novo Nordisk A/S) 21
4.4.5 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 22
4.5 GHD Therapeutics Market – Clinical Pipeline by Mechanism of Action 23
4.5.1 GHD Pipeline – Pipeline by Clinical Phases of Development 23
4.5.2 GHD Therapeutics – Phase III Clinical Pipeline 24
4.5.3 GHD Therapeutics – Phase II Clinical Pipeline 24
4.5.4 GHD Therapeutics – Phase I Clinical Pipeline 24
4.5.5 GHD Therapeutics – Preclinical Phase Pipeline 24
4.6 Key Takeaway 25
5 GHD Therapeutics Market: Implications for Future Market Competition 26
6 GHD Therapeutics Market: Future Players in the GHD Market 28
6.1 Introduction 28
6.2 LG Life Sciences, Korea 29
6.2.1 Overview 29
6.2.2 LB03002 (LG Life Sciences/Biopartners) 29
6.3 Altus Pharmaceuticals, the US 30
6.3.1 Overview 30
6.3.2 ALTU-238 30
6.4 Ambrx, Inc., the US 31
6.4.1 Overview 31
6.4.2 ARX-201 31
6.5 Novo Nordisk A/S, Denmark 32
6.5.1 Overview 32
6.5.2 NN8630 (Novo Nordisk A/S) 33
6.6 Ipsen S.A., France 33
6.6.1 Overview 33
6.6.2 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen) 34
7 GHD Therapeutics Market: Appendix 35
7.1 Market Definitions 35
7.2 Abbreviations 35
7.3 Research Methodology 36
7.3.1 Coverage 36
7.3.2 Secondary Research 37
7.3.3 Forecasting 37
7.3.4 Primary Research 40
7.3.5 Expert Panel Validation 40
7.4 Contact Us 40
7.5 Disclaimer 40
7.6 Sources 41
1.1 List of Tables
Table 1: Neutropenia Market, Revenue ($bn), 2001-2009 7
Table 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Table 3: Major Marketed Products Comparison in the Neutropenia Market, 2010 15
Table 4: Neutropenia Market– Phase III Clinical Pipeline, 2010 22
Table 5: Neutropenia Market– Phase II Clinical Pipeline, 2010 22
Table 6: Neutropenia Market– Pre Clinical Pipeline, 2010 22
Table 7: Neutropenia Market– Terminated Pipeline Molecules, 2010 23
Table 8: Neutropenia Market– Approved Pipeline Molecules, 2010 23
Table 9: Pfizer Pharmaceuticals- Blood Disorder Marketed Products, 2010 29
Table 10: Pfizer Pharmaceuticals- Blood Disorder Pipeline Products, 2010 29
Table 11: Teva Pharmaceuticals- Blood Disorder Marketed Products, 2010 31
Table 12: Teva Pharmaceuticals- Blood Disorder Pipeline Products, 2010 32
1.2 List of Figures
Figure 1: Neutropenia Market, Global, Revenue ($bn), 2001-2009 7
Figure 2: Neutropenia Market, Global, Revenue ($bn), 2009-2016 8
Figure 3: Opportunity and Unmet Need for Neutropenia Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Neutropenia Market, 2010 12
Figure 5: Technology Trends Analytic Framework of the Neutropenia Pipeline, 2010 17
Figure 6: Technology Trends Analytic Framework of the Neutropenia Pipeline – Description, 2010 18
Figure 7: Neutropenia Market – Clinical Pipeline by Mechanism of Action, 2010 21
Figure 8: Neutropenia Pipeline by Phase of Clinical Development, 2010 21
Figure 9: Implications for Future Market Competition in Neutropenia Market, 2010 24
Figure 10: Neutropenia Market – Clinical Pipeline by Company, 2010 25
Figure 11: GlobalData Methodology, 2010 34
Figure 12: GlobalData Market Forecasting Model, 2010 37
Companies mentioned
Maxygen
Pfizer 27
Teva Pharmaceutical Industries Limited
To order this report:
Drug and Medication Industry: Neutropenia - Drug Pipeline Analysis and Market Forecasts to 2016
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
